Antibody Drug Conjugate News and Research

RSS

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

Piramal's Healthcare vertical today announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.

26 Jul 2013

MagnaChip announces full range of "MXsensor" product families

MagnaChip Semiconductor Corporation ("MagnaChip"), a Korean semiconductor company with a broad portfolio of analog and mixed-signal products and technologies, today announced a full range of "MXsensor" intelligent sensor product families featuring 0.18 micron mixed signal & analog technology with low power consumption.

25 Jul 2013

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

AbGenomics International announced today that it has raised $9.6 million in current financing round.

18 Jul 2013

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and BZL Biologics LLC, of New York, today announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers.

15 Jul 2013

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Genmab A/S and ADC Therapeutics Sarl, announced today an agreement to develop a new antibody-drug conjugate product combining Genmab's HuMax-TAC antibody and ADC Therapeutics' PBD-based warhead and linker technology.

17 Jun 2013

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.

17 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Exelixis, Inc. announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone.

11 Apr 2013

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Wolfe Laboratories today announced the presentation of an abstract related to its research efforts surrounding antibody-drug conjugates at the 245th National Meeting of the American Chemical Society, held April 7-11 in New Orleans.

9 Apr 2013

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

A new antibody-guided drug has shown promising activity in a phase I trial involving ovarian cancer patients with platinum drug-resistant disease, researchers from Dana-Farber Cancer Institute will report today at the annual meeting of the American Association for Cancer Research.

8 Apr 2013

Antibody Drug Conjugate News and Research

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

Piramal's Healthcare invests USD 2.5 million to upgrade ADC manufacturing suites

MagnaChip announces full range of "MXsensor" product families

AbGenomics raises $9.6M for advancing therapeutic antibodies for autoimmune diseases, cancers

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Ambrx, ZMC partner to develop and commercialize ARX788 for treatment of Her2-positive breast cancer

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Preclinical study of cabozantinib in prostate cancer bone metastasis model presented at AACR meeting

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Antibody-guided drug shows promising activity in ovarian cancer patients with platinum drug-resistant disease

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Seattle Genetics commences two SGN-CD19A phase I trials in hematologic malignancies

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

NRC, AvidBiologics partner to develop three novel ADCs for treatment of cancer

Drug Discovery - Second Edition eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News